WCM
BCRX icon

Weld Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Weld Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-32,423
Closed -$262K – 651
2018
Q4 		$262K Buy
+32,423
New +$252K 0.06% 532

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Weld Capital Management's BCRX Position: Q1 2019 in Review

Weld Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2019, closing a stake of 32,423 shares — an estimated $262K sold.

Weld Capital Management first reported a position in BCRX in Q4 2018 and held it in 1 quarter. The position peaked at $262K in Q4 2018. 133 funds tracked by Wall St. Rank hold BCRX as of Q1 2019.

  • Weld Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Weld Capital Management sold 32,423 BioCryst Pharmaceuticals shares in Q1 2019, an estimated $262K.
  • Weld Capital Management first reported a position in BioCryst Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Weld Capital Management's BioCryst Pharmaceuticals position peaked at $262K in Q4 2018.
  • 133 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2019.

Based on Weld Capital Management's 13F filing for Q1 2019, filed 15 May 2019.